PRKAG2 syndrome

Article written and reviewed by Dr Luca Moretti

PRKAG2 syndrome is an autosomal dominant cardiac disease in which ventricular hypertrophy, pre-excitation and progressive conduction-system disease result from pathogenic variants in PRKAG2. The gene encodes the regulatory gamma-2 subunit of AMP-activated protein kinase, a sensor that adapts metabolism to energy availability. Its alteration promotes glycogen accumulation and abnormal electrical connections. The resulting metabolic cardiomyopathy may mimic HCM, but has a distinct natural history and risks.

The triad does not always appear simultaneously. A child may present with re-entrant tachycardia and pre-excitation, an adolescent may develop hypertrophy, and an adult may progress to bradycardia or heart block; other members of the same family may have milder expression. Considering the syndrome only when all criteria are present delays diagnosis and necessary device implantation. A longitudinal interpretation connects manifestations that, at different times, may seem like separate diseases.

AMPK and glycogen accumulation

AMPK is a complex formed by catalytic and regulatory subunits that senses energy nucleotides and coordinates ATP consumption and production. PRKAG2 variants alter enzyme sensitivity and glucose pathways, producing excess glycogen in cardiomyocytes. Cells enlarge without the same sarcomeric disarray typical of HCM. The altered energy pathway explains why the same wall thickness can have a different histologic basis.

Glycogen and abnormal development of the fibrous annulus may create connections between atrium, His-Purkinje system and ventricle. Some pathways are atrioventricular and sustain tachycardias, whereas others may be fasciculoventricular and produce a delta wave without participating in a dangerous circuit. Over time, degeneration of the node and specialized tissue causes bradycardia and heart block. The dual electrical vulnerability combines excessive conduction in youth with insufficient conduction later in life.

Different variants, including p.Arg302Gln and p.Asn488Ile, are associated with different ages and severities, but correlations do not perfectly predict the individual patient. Even within a family, wall thickness, arrhythmias and the need for a pacemaker vary. A VUS should not be declared causal merely because it lies in the gene. Genetic validation requires frequency, domain, functional evidence, published cases and segregation.

Known pathogenic variants are largely missense variants and alter nucleotide-binding regions, but the functional mechanism is not identical for every allele. This makes it dangerous to apply a correlation observed in one family to all others. An unexpected truncating or splice variant requires particular verification of the transcript and mechanism. Molecular plausibility must be demonstrated before attributing a common phenotype such as hypertrophy to PRKAG2.

Penetrance increases with age, but onset and components vary. A young carrier may have only ECG abnormalities, whereas an older relative has a pacemaker and hypertrophy; absence of the phenotype at one visit does not contradict segregation. Conversely, a non-carrier relative may develop hypertension or atrial fibrillation from common causes. Time-dependent penetrance prevents variant classification based only on apparently healthy young family members.

Electrocardiogram across the lifespan

In young people, a short PR interval, delta wave and high voltages may be the first signs. Repolarization reflects abnormal activation and hypertrophy; interpreting QT without accounting for QRS duration may overestimate abnormalities. Over time the PR may lengthen, the QRS may change because of block or pacing, and voltages may decrease. The ECG chronology, reconstructed from pediatric and family tracings, often distinguishes an evolving syndrome from isolated WPW.

Pre-excitation may be intermittent, and abrupt loss during exercise suggests a pathway with a longer refractory period but does not eliminate all risk. Adenosine, exercise testing and monitoring provide clues; invasive study directly measures pathway properties and inducibility. In children, the decision and sedation take symptoms and family history into account. Noninvasive assessment selects those who benefit from electrophysiology without using a single sign as a verdict.

Atrial fibrillation may occur at a young age because of atrial disease, the pathway and hypertrophy. If it is pre-excited and very rapid, drugs that block only the atrioventricular node may facilitate accessory conduction and are avoided acutely; cardioversion is indicated when unstable. Management of atrial fibrillation requires staff to recognize an irregular wide-QRS rhythm as a possible accessory-pathway emergency rather than treating it automatically as ordinary AF.

When heart block develops, the accessory pathway may sometimes be the only apparent conduction or may mask the severity of His-Purkinje disease. Ablating it without planning pacing may unmask advanced block. His-bundle recording and nodal assessment clarify the risk. Pathway dependence is a rare but critical situation in which a technically successful procedure may produce unexpected bradycardia.

Electrophysiology study and ablation

Invasive study defines location, refractory period, antegrade and retrograde conduction, number of pathways and inducible tachycardias. Septal pathways close to the node or His bundle increase the risk of ablation-induced block; cryoenergy and conservative strategies may be considered. The target is a clinically relevant circuit, not cosmetic normalization of the ECG. The procedural question should be explicit before catheters are introduced into an already vulnerable conduction system.

A fasciculoventricular pathway connects the His-Purkinje system to the ventricle and does not conduct from the atrium, so it does not produce atrioventricular tachycardia or a rapid ventricular response during AF. Recognizing it avoids dangerous ablation near the His bundle. PRKAG2 syndrome may include different architectures, and not every delta wave is the same. Connection phenotyping is an example of how genetic diagnosis improves, but does not replace, electrophysiology.

After ablation, recurrence, newly apparent pathways, rhythm and conduction are assessed. Loss of the delta wave may make electrical hypertrophy more evident, whereas a lengthening PR requires follow-up. Subsequent palpitations may result from fibrillation or ectopy and do not justify a second empirical ablation. Post-procedure surveillance links immediate success to the progressive disease that continues for decades.

Advanced imaging and tissue diagnosis

Longitudinal strain may fall before ejection fraction, and atrial function may signal atrial-fibrillation risk. The gradient is sought at rest and with appropriate maneuvers; not all dyspnea results from obstruction. Mass must be indexed carefully in children and athletes. Serial measurement uses the same modality and laboratory to distinguish biological growth from technical variability.

CMR measures volumes and LGE and helps distinguish scar from storage, although T1 and ECV are not specific for PRKAG2. Extensive fibrosis supports an arrhythmic substrate and a more advanced phase, but its absence does not eliminate accessory pathways or heart block. A normal CMR in a young carrier does not end surveillance. Tissue characterization complements electrical risk rather than replacing it.

Biopsy shows vacuolated cardiomyocytes rich in glycogen and relative disorganization different from HCM, but findings may overlap with other glycogen storage diseases. It is now reserved for genetically uncertain cases or alternative diagnoses such as myocarditis and storage disorders. Stains and microscopy require dedicated preparation. Targeted biopsy avoids using an invasive specimen to confirm what a familial variant and typical phenotype have already established.

Long-term pacemaker management

Before implantation, atrial rhythm, conduction, function, vascular access and the likelihood of future ICD need are documented. In young people, system longevity, revisions and venous integrity are central; leadless or epicardial devices address specific problems but do not solve every need for dual-chamber pacing or defibrillation. The lifelong strategy considers decades of hardware rather than only the episode of heart block leading to admission.

Chronic right ventricular pacing may cause dyssynchrony and reduced function. Conduction-system pacing or resynchronization is considered according to anatomy, QRS, expected pacing percentage and function; a residual accessory pathway may complicate activation. Prevention of pacing-induced cardiomyopathy is particularly relevant in an already metabolically abnormal myocardium exposed for a long time.

Device checks look not only at battery and thresholds, but also at fibrillation, tachycardias, pacing percentage and changes in intrinsic conduction. A sudden rise in threshold or arrhythmias requires evaluation for common causes and progression. Remote monitoring shortens recognition time without replacing imaging and clinical assessment. Clinical telemetry becomes part of the longitudinal phenotype and may anticipate symptoms.

Heart failure and advanced therapies

When dysfunction develops, the pillars of heart-failure therapy are applied with titration compatible with rhythm, blood pressure and renal function. A pacemaker sometimes permits beta-blockade, but does not eliminate hypotension or low output. SGLT2 inhibitors and mineralocorticoid antagonists have not been tested in PRKAG2 trials but are considered according to phenotype. Transferred evidence should be used transparently, monitoring effects and without promising metabolic correction.

End-stage progression is less uniform than in Danon disease but may require mechanical support or transplantation. Assessment considers arrhythmias, device status, pulmonary vascular resistance and the absence of severe extracardiac disease, generally an advantage over multisystem syndromes. Advanced-therapy candidacy should not be excluded because the gene is rare or delayed until repeated blocks and admissions have exhausted reserve.

Transplantation replaces the heart carrying the defect, and disease is not expected in the graft through systemic transmission; genetic counseling remains necessary for the family. After surgery, arrhythmias of the native heart do not persist, but devices and vascular access must be managed. A favorable extracardiac prognosis may make transplantation appropriate in selected cases with irreversible failure.

Special situations

During pregnancy, volume, heart rate and arrhythmic risk increase. A female carrier is assessed before conception for function, obstruction, rhythm and device status; medications are adapted for the fetus and breastfeeding. Delivery is planned according to risk and does not automatically require cesarean section. Genetic cardio-obstetrics addresses maternal safety and the dominant 50% transmission probability for the child at the same time.

Anesthesia and sedation require information about accessory pathways, heart block, pacemaker, obstruction and function. Medications, electrolytes and pacing are planned, with a magnet or programmer available when indicated. Fasting and dehydration are avoided without attributing to PRKAG2 the systemic metabolic crisis typical of other glycogen storage diseases. Electrical preparation is the specific core of procedural safety.

Drugs that slow the AV node may be dangerous in pre-excited atrial fibrillation, whereas they become useful after ablation or with a pacemaker in different scenarios. Antiarrhythmics must take hypertrophy, function and QT into account; flecainide is not selected without assessing structural heart disease. Circuit-dependent prescribing shows why the same drug may be appropriate in one phase and risky in another.

Quality of familial diagnosis

The proband should receive a report specifying transcript, classification, evidence and a reassessment plan. A pathogenic variant guides targeted testing; a VUS should not be used to exclude a relative from clinical follow-up or to implant a device. Genetic documentation prevents the same family from receiving discordant diagnoses at different centers.

Testing in minors is justified because pre-excitation and heart block may appear early and surveillance changes safety. Timing and communication should respect maturity and psychological impact, including school and sports. A positive result does not mean a permanent ban; it leads to assessment and a plan. Pediatric utility derives from the concrete possibility of preventing syncope, tachycardia and heart block.

Sudden death in a young relative can be investigated with expert cardiac autopsy and post-mortem testing, preserving DNA and tissue. The result clarifies risk in living relatives and may distinguish PRKAG2 from other cardiomyopathies. Molecular autopsy is part of prevention and requires consent, sample chain of custody and interpretation with the family phenotype.

Structural phenotype

Hypertrophy is often concentric, but may be asymmetric and sometimes obstructive. Systolic and diastolic function may remain preserved for years or evolve toward dilation, fibrosis and heart failure. Echocardiography documents mass, obstruction, atria and function, whereas CMR describes distribution and scar. There is no exclusive LGE pattern. Nonspecific morphology gains value only together with the ECG and family history.

Dyspnea may result from diastolic dysfunction, arrhythmia or chronotropic incompetence; syncope may result from tachycardia, block or obstruction. A normal ejection fraction does not exclude low reserve from a slow rhythm or small cavity. During follow-up, volumes and function should be interpreted in relation to pacing percentage, because chronic right ventricular pacing may add dyssynchrony. Combined physiology distinguishes disease progression from device-related consequences.

Pre-excitation and tachyarrhythmias

A short PR and delta wave may appear early and be accompanied by atrioventricular tachycardias, atrial fibrillation or flutter. A rapidly conducted atrial fibrillation through an accessory pathway may degenerate into a ventricular arrhythmia, but not all delta waves carry this risk. Electrophysiology study assesses pathway properties, mechanism and the indication for ablation. Pathway stratification avoids both false reassurance and ablation of benign connections close to the normal conduction system.

Ablation treats an accessory pathway or circuit, not the genetic disease. Multiple pathways, proximity to the His bundle and progression of conduction disease increase complexity; a successful procedure does not end surveillance. Drugs that slow the AV node should be used cautiously in pre-excited atrial fibrillation and in patients progressing toward heart block. Arrhythmia therapy must anticipate the subsequent need for pacing.

Bradycardia, heart block and devices

Sinus-node dysfunction and atrioventricular block are central features and may require a pacemaker at a young age. Palpitations that disappear do not necessarily mean improvement: they may reflect loss of conduction. Serial ECGs, exercise testing and monitoring detect pauses and chronotropic incompetence. Conduction progression is a reason to follow even a carrier who still has little hypertrophy.

Device selection considers the likelihood of complete block, ventricular function, need for defibrillation and the expected high pacing burden. In a patient with fibrosis or dysfunction, an ICD or more physiologic pacing may be preferable to simple right ventricular pacing; however, there is no automatic genotype-based indication. Anticipatory design avoids repeated upgrades and preserves the ventricle.

Sudden death may result from pre-excited fibrillation, ventricular tachycardia, heart block or heart failure. Cardiac arrest and sustained tachycardia indicate secondary prevention; in primary prevention, unexplained syncope, dysfunction, LGE, arrhythmias and family history are integrated. Sarcomeric HCM calculators are not validated for PRKAG2. Specific risk stratification requires multidisciplinary judgment and reassessment over time.

Differential diagnosis

Sarcomeric HCM may coexist with an accessory pathway by chance, but a familial combination of pre-excitation and heart block is more suggestive of PRKAG2. Danon disease tends toward more extreme hypertrophy, early male onset, elevated CK, myopathy and cognitive difficulties. Infantile Pompe disease presents with cardiorespiratory hypotonia; Fabry disease adds neuropathy, renal involvement and low T1. Syndromic comparison selects targeted tests without assuming that every delta wave is metabolic.

Phenocopies may overlap and cardiomyopathy panels often include several genes. A correctly classified PRKAG2 variant consistent with inheritance and phenotype confirms the diagnosis; biopsy showing vacuoles and glycogen is rarely necessary. CK and extracardiac manifestations are generally less prominent than in Danon disease. Diagnostic parsimony must not become a shortcut: coexistence of variants or common causes remains possible.

Treatment and physical activity

There is no approved therapy capable of normalizing AMPK or selectively removing cardiac glycogen. Heart failure and obstruction are treated according to phenotype, adapting beta-blockers and other drugs to the risk of bradycardia. Ablation reduces appropriate tachycardias, while pacing and ICDs prevent selected complications. Component-based care requires a single center that avoids contradictory decisions between electrophysiology and cardiomyopathy teams.

Physical activity is prescribed after assessment of obstruction, arrhythmias, conduction and device status. Moderate recreational exercise may be possible, whereas intense competitive sport requires shared decision-making and reassessment; syncope, tachycardia or heart block require caution. Complete sedentary behavior harms health and is not a genetic therapy. Individualized prescription replaces uniform prohibitions.

Family screening and prognosis

A pathogenic variant enables cascade testing. Each child of a heterozygous individual has a 50% chance of inheriting it, and both men and women can transmit and manifest it. Carriers undergo ECG and echocardiography even when asymptomatic, with monitoring calibrated to age and variant; non-carriers of the familial variant may be discharged from gene-specific surveillance. Family prevention identifies blocks and pathways before syncope or cardiac arrest.

Prognosis is variable. Many patients live for a long time with a pacemaker and preserved function; others develop arrhythmias, heart failure or sudden death. Variant, age at onset, fibrosis and dysfunction contribute, but no parameter provides individual certainty. Follow-up that links rhythm and structure is more useful than a one-time prediction. Dynamic prognosis is updated with every change in conduction, arrhythmia or function.

The follow-up plan specifies who checks the device and who reassesses the cardiomyopathy, preventing each service from assuming that the other is responsible. Remote ECG does not measure mass, whereas CMR does not detect an intermittent pause. Shared responsibility combines electrophysiology, imaging and genetics in a single schedule that the patient can understand.

Chest pain and troponin require standard ischemic and inflammatory assessment: PRKAG2 does not make coronary disease or myocarditis impossible. Likewise, new hypertension may accelerate hypertrophy. Nonexclusive diagnosis prevents the gene from becoming a universal explanation and keeps acquired conditions that arise with age treatable.

Occupational risk is assessed for jobs involving driving, working at height, weapons or public safety, in which syncope or a shock has particular consequences. Restrictions are based on regulations, rhythm and stability and are reassessed after treatment. Proportionate fitness assessment avoids both exclusion based solely on genotype and ignoring genuinely dangerous conduction disease.

Psychological support may be useful for people living with an early device or who have lost relatives suddenly. Uncertainty is not resolved by promising absolute safety after ablation. Risk communication distinguishes what a pacemaker prevents, what an ICD can terminate and what depends on mechanical progression.

Variant and phenotype registries should distinguish pathways, heart block, device type, mass and function. Small series may overestimate severity because they recruit from tertiary centers, whereas mildly affected families remain undiagnosed. Unselected epidemiology is necessary for genotype-phenotype correlations and future studies of targeted metabolic therapies.

Reproductive counseling includes natural conception, prenatal diagnosis and preimplantation testing according to preferences and regulations, but does not present penetrance as certain severity. Each child who inherits the variant may have different expression. Reproductive choice requires neutral information about the 50% risk, variability and the possibility of early surveillance.

A family record containing historical ECGs, variants and devices helps recognize the pattern and reduces repetition. With consent, sharing the correct report among relatives facilitates targeted testing. Family memory transforms scattered events into a useful natural history and prevents each new case from starting again with a diagnosis of isolated WPW.

The center periodically reassesses variant classification and new therapeutic evidence. Updated care avoids both missing future opportunities and adopting experimental metabolic treatments before safety and clinical benefit are truly demonstrated.